Mid Year In Review Multiple Sclerosis 2018
Pain in patients with multiple sclerosis may affect their daily functioning regardless of disease severity.
Differing formulations and ratios of the subjects' medical cannabis regimens have been accounted for, though further information about ratios of CBD and TCH are subject to change due to continued ongoing research.
The study researchers examined data from the US database of the IMS Health Real World Data Adjudicated Claims between 2011 and 2015.
Although the study demonstrated a lower relapse rate among patients with MS who supplemented their diet with vitamin D, the analysis did not reach statistical significance.
The FDA's decision was based on data from the Phase 3 PARADIGMS study (N=215) which evaluated the safety and efficacy of oral fingolimod vs interferon beta-1a injection in pediatric patients aged 10 to <18 years with relapsing MS.
Investigators designed a parallel-group, 2-arm, randomized controlled trial to evaluate ELEVIDA, an online fatigue management program based on cognitive behavioral therapy and other therapy-based strategies.
A regression model showed that efficacy of DMTs significantly decreased until age 53, after which disease progression is not affected by DMTs.
A cross-sectional study aimed to assess the effect of smoking and alcohol consumption along with the interactions they have on the clinical course of multiple sclerosis.
Participants who were treated with both doses of fingolimod experienced less overall progression of disability than those receiving placebo.
Further research should focus on establishing whether siponimod exerts its effect on the pathogenic processes associated with disease progression or activity, or both.
The effect of 8 weeks of combined exercise training on serum BDNF concentration was examined in patients with relapsing-remitting multiple sclerosis.
Daclizumab, an interleukin-2 (IL-2) receptor blocking antibody, was approved in May 2016 to treat adults with relapsing forms of MS.
The association suggests that caffeine consumption may play a protective role against multiple sclerosis-related disability.
Vitamin D deficiency is a risk factor for multiple sclerosis.
Intakes of fats and types of fatty acids may affect disability severity in multiple sclerosis and neuromyelitis optica spectrum disorder.
A 55-year-old woman with multiple sclerosis and no history of thyroid disease developed lab abnormalities suggestive of thyrotoxicosis on routine testing.
A significant unmet need remains for an effective, well-tolerated, and convenient treatment for patients with progressive forms of MS.
Authors describe 2 case reports of MS in the pediatric population after administration of HPV vaccination.
Researchers sought to compare 2010 McDonald and MAGNIMS criteria for predicting conversion to MS from clinically isolated syndrome.
While both intravenous and oral administrations of methylprednisolone showed similar efficacy, the investigators noted that oral administration may be more tolerable and cost-effective.
Neurology Advisor Articles
- US Opioid Overdose Deaths Reach Record Number
- Migraine Treatment in the ED: Overcoming Our Penchant for Opioids
- Erenumab as a Therapy for Hard to Treat Episodic Migraine
- Abnormalities in Genes Linked to IRSP in Alzheimer Disease
- Recommended Levels of Cardiovascular Risk Factors Associated With Cerebral Vessel Density, Flow
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Addressing Levodopa-Resistant Parkinson Disease
- High Daily Stress Linked to Migraine Prevalence in Women
- Researchers Identify Coffee Component That May Provide Neuroprotection
- Functional Imaging in Movement Disorders: Diagnostic Advantages
- Dextroamphetamine Plus Physical Therapy Nonsuperior to Placebo for Improving Post-Stroke Motor Recovery
- Nusinersen May Be Effective for Short-Term Motor Function Improvements in Spinal Muscular Atrophy